Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells

Autor: Paul W. H. I. Parren, Marleen Voorhorst, Patrick J. Engelberts, Tom Vink, Frank J. Beurskens, Thomas Valerius, Wendy J.M. Mackus, Joost M. Bakker, Stefanie Derer, Tom van Meerten, Esther C.W. Breij, Janine Schuurman, Jan G. J. van de Winkel

Publikováno v: Engelberts, P J, Voorhorst, M, Schuurman, J, Van Meerten, T, Bakker, J M, Vink, T, Mackus, W J M, Breij, E C W, Derer, S, Valerius, T, van de Winkel, J G J, Parren, P W H I & Beurskens, F J 2016, ' Type i CD20 antibodies recruit the B cell receptor for complement-dependent lysis of malignant B cells ', Journal of Immunology, vol. 197, no. 12, pp. 4829-4837 . https://doi.org/10.4049/jimmunol.1600811
Journal of Immunology, 197(12), 4829-4837. AMER ASSOC IMMUNOLOGISTS

Human IgG1 type I CD20 Abs, such as rituximab and ofatumumab (OFA), efficiently induce complement-dependent cytotoxicity (CDC) of CD20+ B cells by binding of C1 to hexamerized Fc domains. Unexpectedly, we found that type I CD20 Ab F(ab')2 fragments,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d9197ec28f899d5e6a016465f31efa
https://portal.findresearcher.sdu.dk/da/publications/34aca668-9af2-49ed-945c-3a69d108b381